SEOM clinical guideline on heritable TP53-related cancer syndrome (2022)
Clin. transl. oncol. (Print)
; 25(9): 2627-2633, sept. 2023.
Article
in En
| IBECS
| ID: ibc-224129
Responsible library:
ES1.1
Localization: ES15.1 - BNCS
ABSTRACT
Li-Fraumeni syndrome is caused by heterozygous germline pathogenic variants in the TP53 gene. It involves a high risk of a variety of malignant tumors in childhood and adulthood, the main ones being premenopausal breast cancer, soft tissue sarcomas and osteosarcomas, central nervous system tumors, and adrenocortical carcinomas. The variability of the associated clinical manifestations, which do not always fit the classic criteria of Li-Fraumeni syndrome, has led the concept of SLF to extend to a more overarching cancer predisposition syndrome, termed hereditable TP53-related cancer syndrome (hTP53rc). However, prospective studies are needed to assess genotypephenotype characteristics, as well as to evaluate and validate risk-adjusted recommendations. This guideline aims to establish the basis for interpreting pathogenic variants in the TP53 gene and provide recommendations for effective screening and prevention of associated cancers in carrier individuals (AU)
Key words
Full text:
1
Collection:
06-national
/
ES
Database:
IBECS
Main subject:
Tumor Suppressor Protein p53
/
Li-Fraumeni Syndrome
/
Genetic Predisposition to Disease
Limits:
Humans
Country/Region as subject:
Europa
Language:
En
Journal:
Clin. transl. oncol. (Print)
Year:
2023
Type:
Article